Biocardia Inc (BCDA)

$2.18 +0.06 (2.78%)
Market Cap 9.72M
Revenue (ttm) 480,000.00
Net Income (ttm) -11.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,410.42%
Debt to Equity Ratio 0.00
Volume 16,100
Avg Vol 45,728
Day's Range N/A - N/A
Shares Out 4.58M
Stochastic %K 40%
Beta 1.26
Analysts Strong Sell
Price Target $25.00

Latest News on BCDA

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Dec 4, 2024, 8:30 AM EST - 6 weeks ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:49 PM EST - 2 months ago

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 18, 2024, 8:30 AM EDT - 4 months ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Sep 9, 2024, 4:05 PM EDT - 4 months ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 29, 2024, 8:30 AM EDT - 5 months ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 21, 2024, 7:00 AM EDT - 5 months ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:53 PM EDT - 5 months ago

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 13, 2024, 4:30 PM EDT - 5 months ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jul 17, 2024, 7:00 AM EDT - 6 months ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

Jun 7, 2024, 7:00 AM EDT - 8 months ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

BioCardia Announces Reverse Stock Split

May 21, 2024, 5:00 PM EDT - 8 months ago

BioCardia Announces Reverse Stock Split

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:00 PM EDT - 8 months ago

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 14, 2024, 4:02 PM EDT - 8 months ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 9, 2024, 7:00 AM EDT - 9 months ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

May 1, 2024, 7:00 AM EDT - 9 months ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Apr 25, 2024, 9:00 AM EDT - 9 months ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 8:00 PM EDT - 10 months ago

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 27, 2024, 4:00 PM EDT - 10 months ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 20, 2024, 7:00 AM EDT - 10 months ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 13, 2024, 7:00 AM EDT - 11 months ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 12, 2024, 7:00 AM EDT - 11 months ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Mar 4, 2024, 8:00 AM EST - 11 months ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Feb 8, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Jan 31, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Dec 19, 2023, 7:00 AM EST - 1 year ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

Dec 18, 2023, 7:16 AM EST - 1 year ago

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

Nov 29, 2023, 7:00 AM EST - 1 year ago

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Nov 16, 2023, 12:56 PM EST - 1 year ago

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Nov 14, 2023, 7:15 AM EST - 1 year ago

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 8:08 PM EST - 1 year ago

BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript

BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 8, 2023, 4:11 PM EST - 1 year ago

BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

Nov 1, 2023, 5:04 PM EDT - 1 year ago

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

Oct 11, 2023, 6:00 AM EDT - 1 year ago

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

Sep 6, 2023, 7:15 AM EDT - 1 year ago

BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Sep 5, 2023, 7:15 AM EDT - 1 year ago

BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia, Inc. (BCDA) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 5:45 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q2 2023 Earnings Call Transcript

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

Aug 9, 2023, 4:05 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023

Aug 2, 2023, 7:00 AM EDT - 1 year ago

BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

Jul 24, 2023, 7:00 AM EDT - 1 year ago

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

Jul 5, 2023, 7:00 AM EDT - 1 year ago

BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study

Jun 20, 2023, 5:14 PM EDT - 1 year ago

BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study

BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan

Jun 8, 2023, 7:00 AM EDT - 1 year ago

BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan

BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

May 23, 2023, 7:00 AM EDT - 1 year ago

BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

BioCardia, Inc. (BCDA) Q1 2023 Earnings Call Transcript

May 10, 2023, 8:25 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q1 2023 Earnings Call Transcript

BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

May 10, 2023, 4:05 PM EDT - 1 year ago

BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

May 9, 2023, 7:00 AM EDT - 1 year ago

BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

May 3, 2023, 8:00 PM EDT - 1 year ago

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

Apr 28, 2023, 7:00 AM EDT - 1 year ago

BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

Apr 4, 2023, 7:00 AM EDT - 1 year ago

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies